Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

Clinical Trial ID NCT00974311

PubWeight™ 68.65‹?›

🔗 Visit the page for NCT00974311

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012 20.79
2 Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014 3.03
3 Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2011 2.68
4 Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011 2.17
5 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
6 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
7 End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011 1.94
8 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
9 Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2011 1.64
10 Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol 2014 1.47
11 Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int 2014 1.43
12 Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet 2015 1.42
13 Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J 2011 1.25
14 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
15 Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 2010 1.22
16 Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013 1.16
17 Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011 1.14
18 Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011 1.05
19 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
20 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
21 Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013 1.00
22 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
23 Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011 0.94
24 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
25 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
26 Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol 2014 0.88
27 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
28 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
29 Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 2013 0.83
30 Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2010 0.82
31 Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013 0.82
32 Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci 2016 0.81
33 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
34 Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines 2011 0.80
35 Abiraterone acetate. Nat Rev Drug Discov 2011 0.80
36 Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. Ther Adv Urol 2012 0.80
37 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
38 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
39 An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol 2015 0.79
40 A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012 0.78
41 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
42 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
43 2012 CUA Abstracts. Can Urol Assoc J 2012 0.75
44 High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 2015 0.75
45 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
Next 100